Skip to content


  • Letter
  • Open Access

Presepsin and sepsis-induced acute kidney injury treated with continuous renal replacement therapy: will another promising biomarker bite the dust?

  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care201519:428

  • Published:

The original article was published in Critical Care 2015 19:323


  • Glomerular Filtration Rate
  • Septic Shock
  • Glomerular Filtration
  • Chronic Renal Failure
  • Systemic Inflammation

A recent meta-analysis published in Critical Care proposed presepsin as a novel valuable biomarker for discriminating systemic inflammation from true sepsis [1]. Unfortunately, this excellent paper did not provide information about the occurrence and eventual treatment of acute kidney injury (AKI) in the studied population. The kidney is one of the most frequently afflicted organs during sepsis and AKI may complicate up to half of the cases of blood culture-positive septic shock [2].

Little information is available on presepsin in patients with kidney dysfunction except that levels tend to increase with digressive glomerular filtration rate and are markedly high in patients with chronic renal failure or receiving hemodialysis [3]. More importantly, continuous renal replacement therapy (CRRT) is increasingly used to treat AKI in critically ill patients. C-reactive protein and procalcitonin, which are actually the most commonly used biomarkers to support diagnosis and to evaluate treatment in septic patients, are both significantly eliminated during CRRT [4].

Presepsin is fragmented from a larger glycoprotein and has a molecular weight of approximately 13 kDa. This is of particular concern because it theoretically exposes presepsin to significant convective elimination. Presepsin clearance may even be higher than expected because the molecule may “stick” to the highly adsorptive membranes incorporated in modern CRRT devices [5]. Thus, presepsin cannot be proposed as an accurate and clinically relevant sepsis biomarker until its behavior during CRRT is better specified.




Acute kidney injury


Continuous renal replacement therapy


Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

ICU Department, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, 1090, Belgium


  1. Zhang X, Liu D, Liu YN, Wang R, Xie LX. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit Care. 2015;19:323.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the Systemic Inflammatory Response Syndrome (SIRS): a prospective study. JAMA. 1995;273:117–23.View ArticlePubMedGoogle Scholar
  3. Nagata T, Yasuda Y, Ando M, Abe T, Katsuno T, Kato S, et al. Clinical impact of kidney function on presepsin levels. PLoS One. 2015;10, e0129159.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Honore PM, Jacobs R, Hendrickx I, De Waele E, Van Gorp V, Spapen HD. ‘Biomarking’ infection during continuous renal replacement therapy: still relevant? Crit Care. 2015;19:232.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, De Waele E, van Gorp V, et al. Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO J. 2013;59:99–106.View ArticlePubMedGoogle Scholar


© Honore et al. 2015